ORG-12962

ORG-12962 is a pyridinylpiperazine drug developed by Organon, which acts as a potent and selective agonist for the 5-HT₂ receptor family, with highest affinity at 5-HT_2C and lowest at 5-HT_2B subtypes.[1] It was developed as a potential anti-anxiety drug, but was discontinued from human trials after tests in a public speaking challenge showed that its anti-anxiety effects were accompanied by side effects such as dizziness and a "spacey" feeling, which were attributed to poor selectivity in vivo over the hallucinogenic 5-HT_2A receptor.[2]

ORG-12962

Legal status
Legal status	In general: uncontrolled
Identifiers
IUPAC name 1-(5-trifluoromethyl-6-chloropyridin-2-yl)piperazine
CAS Number	210821-63-9
PubChem CID	9796408
IUPHAR/BPS	170
ChemSpider	7972174
ChEMBL	ChEMBL506999
CompTox Dashboard (EPA)	DTXSID70430870
Chemical and physical data
Formula	C10H11ClF3N3
Molar mass	265.66 g·mol^−1
3D model (JSmol)	Interactive image
SMILES C2CNCCN2c(nc1Cl)ccc1C(F)(F)F
InChI InChI=1S/C10H11ClF3N3/c11-9-7(10(12,13)14)1-2-8(16-9)17-5-3-15-4-6-17/h1-2,15H,3-6H2 Key:QZYYPQAYSFBKPW-UHFFFAOYSA-N
(what is this?)  (verify)

See also

• 2C-B-PP
• 2,3-Dichlorophenylpiperazine
• 3-Chloro-4-fluorophenylpiperazine
• CPD-1
• ORG-37684
• Quipazine

References

1. Porter RH, Benwell KR, Lamb H, Malcolm CS, Allen NH, Revell DF, Adams DR, Sheardown MJ (September 1999). "Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells". British Journal of Pharmacology. 128 (1): 13–20. doi:10.1038/sj.bjp.0702751. PMC 1571597. PMID 10498829.
2. Monck NJ, Kennett GA (2008). "5-HT2C ligands: recent progress". Progress in Medicinal Chemistry. 46: 281–390. doi:10.1016/S0079-6468(07)00006-9. ISBN 9780444530189. PMID 18381128.